ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and treatment"

  • Abstract Number: 2385 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study

    Runyue Huang1, Qingchun Huang 2, Jiaqi Wu 3, Xiao Cai 4, Xiumin Chen 4, Yue Zhao 4, Yongliang Chu 2, Jianyong Zhang 5, Jianhong Peng 6, Zhisheng Huang 7, Xianghong Chen 2, Zehao Liu 8 and Aihua Ou 2, 1The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China;, Guangzou, Guangdong, China (People's Republic), 2The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic), 3Section Rheumatology Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzou, China (People's Republic), 4The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzou, China (People's Republic), 5Shenzhen Hospital of Traditional Chinese Medicine, Shenzhen, China (People's Republic), 6Dongguan Hospital of Traditional Chinese Medicine, Dongguan, China (People's Republic), 7Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Huandu, China (People's Republic), 8Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic)

    Background/Purpose:  In recent years, the combination therapies of conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) with Chinses medicine has prevailed for the treatment of rheumatoid arthritis…
  • Abstract Number: 579 • 2018 ACR/ARHP Annual Meeting

    Changes in DNA Methylation Identify Response to Treatment with Methotrexate and TNF Inhibitors Among RA Patients

    Cameron Adams1, Katie Marker1, Melissa Krueger2, Lisa Barcellos1 and Lindsey A. Criswell3, 1School of Public Health, UC Berkeley, Berkeley, CA, 2UC San Francisco, San Francisco,, CA, 3University of California San Francisco, San Francisco, CA

    Background/Purpose: Epigenetic modifications including DNA methylation are implicated in the development and progression of autoimmune diseases, such as rheumatoid arthritis  [MIM 180300]. Evidence indicates that…
  • Abstract Number: 2549 • 2018 ACR/ARHP Annual Meeting

    Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study

    Vibeke Strand1, Matthew Reaney2, Erin Mangan3, Hubert van Hoogstraten4, Susan Boklage3 and Chih-Chi Hu5, 1Stanford University School of Medicine, Palo Alto, CA, 2Sanofi, Guildford, United Kingdom, 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Sanofi Genzyme, Bridgewater, NJ, 5Sanofi, Bridgewater, NJ

    Background/Purpose: Sarilumab is a human monoclonal antibody that binds to membrane and soluble IL-6R, which is approved for the treatment of moderate to severe rheumatoid…
  • Abstract Number: 587 • 2018 ACR/ARHP Annual Meeting

    The Superiority of a Treat to Target Strategy over Conventional Treatment with Fixed Csdmard and Corticosteroids: A Multi-Centre Randomized Controlled Trial in RA Patients with Inadequate Response to Conventional Synthetic Dmards, and a New Therapy with Certolizumab Pegol

    Ruediger Mueller1, Michael Spaeth2, Cord von Restorff3, Christoph Ackermann4 and Johannes von Kempis5, 1Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, 2Division of Rheumatology, Spital Linth, Uznach, Switzerland, 3Private rheumatologic practice, Männedorf, Switzerland, 4Private rheumatologic practice, Triesen, Liechtenstein, 5Division of Rheumatology and Immunology, Kantonsspital St. Gallen, St. Gallen, Switzerland

    The superiority of a treat to target strategy over conventional treatment with fixed csDMARD and corticosteroids: a multi-centre randomized controlled trial in RA patients with…
  • Abstract Number: 2870 • 2018 ACR/ARHP Annual Meeting

    Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions

    Brian C. Sauer1, Chia-Chen Teng, MS1, Neil A. Accortt2, David H. Collier2, Tzu-Chieh Lin2 and Grant W. Cannon1, 1Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2Amgen Inc., Thousand Oaks, CA

    Background/Purpose:   Treatment guidelines recommend using disease activity measures (DAMs) to guide RA therapy, but DAM use in real-world treatment decisions is not defined.  We…
  • Abstract Number: 604 • 2018 ACR/ARHP Annual Meeting

    Combining Observational and Randomized Controlled Trial Data Evidence to Jointly Estimate Remission and Response for Biologic and Non-Biologic Therapies in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis

    Gyanendra Pokharel1, Rob Deardon1, Cheryl Barnabe2, Vivian P. Bykerk3, Susan J. Bartlett4, Louis Bessette5, Gilles Boire6, Carol Hitchon7, Edward C. Keystone8, Janet E. Pope9, Diane Tin10, Carter Thorne11 and Glen Hazlewood12, 1Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, 2Medicine, University of Calgary, Calgary, AB, Canada, 3Hospital for Special Surgery, New York, NY, 4Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 5Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, 6Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8Mount Sinai Hospital, Toronto, ON, Canada, 9Department of Medicine, University of Western Ontario, London, ON, Canada, 10The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 11University of Toronto, Newmarket, ON, Canada, 12Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada

    Background/Purpose: Remission is the goal of rheumatoid arthritis (RA) treatment, but ACR responses are more commonly measured in clinical trials. As such, data on remission…
  • Abstract Number: 2875 • 2018 ACR/ARHP Annual Meeting

    Identifying Trends in Lines of Therapy Following Initial Biologic Disease-Modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis

    Jay Lin1, Jeannie Choi2, Jeffrey R. Curtis3, Melissa Lingohr-Smith1 and Susan Boklage4, 1Novosys Health, Green Brook, NJ, 2Sanofi, Bridgewater, NJ, 3University of Alabama at Birmingham, Birmingham, AL, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY

    Background/Purpose: Among patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), the addition of a biologic DMARD…
  • Abstract Number: 884 • 2018 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Disease Activity Predicting Incident Clinically-Apparent Interstitial Lung Disease: A Prospective Cohort Study

    Jeffrey A. Sparks1, Tracy Doyle2, Jie Huang1, Beatrice Pan2, Elaine Fletcher2, Ritu Gill3, Hiroto Hatabu2, Mizuki Nishino4, David Murphy2, Taysir Mahmoud2, Christine K Iannaccone5, Michelle Frits2, Bing Lu6, Ivan O. Rosas7, Paul Dellaripa2, Michael E Weinblatt5, Elizabeth Karlson6 and Nancy A. Shadick2, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Beth-Israel Deaconess Medical Center, Boston, MA, 4Dana-Farber Cancer Institute, Boston, MA, 5Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 6Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 7BWH - Pulmonary, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Determining modifiable risk factors for interstitial lung disease (ILD) is crucial given its substantial morbidity/mortality. Treatment to target of remission/low disease activity improves articular…
  • Abstract Number: 2982 • 2018 ACR/ARHP Annual Meeting

    Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up

    Pomme Poppelaars1, Lilian van Tuyl2 and Maarten Boers1,3, 1Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, 3Epidemiology & Biostatistics, Epidemiology & Biostatistics | VU University Medical Center, Netherlands, Amsterdam, Netherlands

    ACR abstractBackground/Purpose: Mortality in patients with rheumatoid arthritis (RA) is higher than in the general population. In most studies this becomes apparent only after more…
  • Abstract Number: 1502 • 2018 ACR/ARHP Annual Meeting

    Predicting Response to Methotrexate Therapy in New-Onset RA: No Value of Adding Protein Biomarkers to Clinical Predictors

    Xavier M Teitsma1, Johannes W. G. Jacobs2, Pascal HP de Jong3, JMW Hazes3, Angelique EAM Weel3,4, Paco MJ Welsing1, Attila Pethö-Schramm5, Michelle EA Borm6, Jacob van Laar1, Johannes W. J. Bijlsma7 and Floris PJG Lafeber8, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, 2Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, 4Rheumatology, Maastad Hospital, Rotterdam, Netherlands, 5F. Hoffmann-La Roche, Basel, Switzerland, 6Roche Nederland BV, Woerden, Netherlands, 7Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 8Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: We previously identified higher disease activity score assessing 28 joints (DAS28) at baseline, current smoking and no alcohol consumption as clinical predictors for inadequate…
  • Abstract Number: 2985 • 2018 ACR/ARHP Annual Meeting

    Achievement of Remission in Two Early Rheumatoid Arthritis Inception Cohorts Implementing Different Treat-to-Target Strategies

    Vibeke Norvang1,2, Gina Hetland Brinkmann1,3, Joseph Sexton1, Anna-Birgitte Aga1, Siri Lillegraven1, Till Uhlig1,2, Tore Kvien1,2, Maria Dahl Mjaavatten1 and Espen A. Haavardsholm1,2, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2University of Oslo, Oslo, Norway, 3Dept. of Rheumatology, Østfold Hospital, Grålum, Norway

    Background/Purpose: Treat-to-target (T2T) has become a key element in the management of rheumatoid arthritis (RA). Several different measures exist to define the preferred treatment target…
  • Abstract Number: 1889 • 2018 ACR/ARHP Annual Meeting

    Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population

    Beth Wallace1,2,3, Paul Lin2,4, Neil Kamdar2,4, Mohamed Noureldin2,3,5, Rodney Hayward2,3,6, David A. Fox1, Jeffrey R. Curtis7, Kenneth Saag8 and Akbar Waljee2,3,9, 1Department of Internal Medicine, Division of Rheumatology, Michigan Medicine, Ann Arbor, MI, 2University of Michigan Institute for Healthcare Policy and Innovation, Ann Arbor, MI, 3Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, 4University of Michigan Medical School, Ann Arbor, MI, 5Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, 6Department of Internal Medicine, Division of General Medicine, Michigan Medicine, Ann Arbor, MI, 7University of Alabama at Birmingham, Birmingham, AL, 8University of Alabama, Birmingham, AL, 9Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI

    Background/Purpose: Glucocorticoids (GC) reduce RA-related disability and joint damage; RA guidelines endorse short term use during DMARD initiation and flares. Long-term high-dose GC exposure (>3…
  • Abstract Number: 1923 • 2018 ACR/ARHP Annual Meeting

    Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?

    Elena Nikiphorou1, Sam Norton2, Adam Young3, Lewis Carpenter2, Josh Dixey4, David Walsh5 and Patrick Kiely6, 1Academic Rheumatology, Department of Inflammation Biology, King's College London, London, Great Britain, 2Academic Rheumatology, King's College London, London, United Kingdom, 3University of Hertfordshire, Hertford, United Kingdom, 4Rheumatology, The Royal Wolverhampton, Wolverhampton, United Kingdom, 5Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, 6Rheumatology Dept, St Georges Hospital, London, Great Britain

    Treating Rheumatoid Arthritis To Target: Is Low Disease Activity Good Enough? Background/Purpose:  It is now widely recognised that treat-to-target (T2T) principles in rheumatoid arthritis (RA)…
  • Abstract Number: 1937 • 2018 ACR/ARHP Annual Meeting

    Low-Dose IL-2 Restored Reduced Regulatory T Cells in Patients with Rheumatoid Arthritis

    Ming Yan1, Sheng-Xiao Zhang2, Ruihuan Jia2, Yu-Fei Hao1, He-Hua Sun1, Yan-Yan Wang1, Guang-Ying Liu1, Cai-Hong Wang3, Chong Gao4 and Xiao-Feng Li3, 1Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, 2The Second Hospital of Shanxi Medical University, Taiyuan, China, 3The Second Hospital of Shanxi Medical Univerity, Taiyuan, China, 4Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA

    Background/Purpose: Patients with rheumatoid arthritis (RA) have lymphocyte dysfunction characterized by deficiency or dysfunction of regulatory T cells (Tregs), which plays crucial roles in immune tolerance. Low dose IL-2…
  • Abstract Number: 1938 • 2018 ACR/ARHP Annual Meeting

    A Phase IIb Dose-Ranging Study of Anti-GM-CSF with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate

    Chris Buckley1, Jesus A Simon Campos2, Sergey Yakushin3, Vyacheslav Zhdan4, Katherine Davy5, David Inman6, Elena Fisheleva7,8, Anubha Gupta8, Mark Layton9, Nina Mitchell7,8, Jatin Patel10, Russell Williamson6 and Paul-Peter Tak11, 1University of Birmingham, Birmingham, United Kingdom, 2Hospital CEM/BIOCEM, Merida, Mexico, 3Ryazan Regional Clinical Cardiology Dispensary, Ryazan, Russian Federation, 4M.V.Sklifosovskyi Poltava Regional Clinical Hospital, Poltava, Ukraine, 5Statistics, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 6GlaxoSmithKline, Stockley Park, United Kingdom, 7Currently at Biomarin UK Ltd, London, United Kingdom, 8GlaxoSmithKline, Stevenage, United Kingdom, 9ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 10ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 11University of Cambridge, Cambridge and GlaxoSmithKline, Stevenage, United Kingdom

    Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing. This study evaluated the efficacy…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology